![](/img/cover-not-exists.png)
The First Placebo-Controlled Trial in Cryopyrin-Associated Periodic Syndromes (CAPS): IL-1 Trap (rilonacept) Markedly Reduces Clinical and Laboratory Abnormalities in Patients with Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)
Hoffman, H.M., Weinstein, S.P., Amar, N.J., Throne, M.L., Boling, E.P., Grimes, I.M., Belomestnov, P., Stein, D.R., Vicary, C., Mellis, S.J.Volume:
119
Language:
english
Journal:
Journal of Allergy and Clinical Immunology
DOI:
10.1016/j.jaci.2006.12.631
Date:
February, 2007
File:
PDF, 43 KB
english, 2007